187 related articles for article (PubMed ID: 19950289)
21. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
Prey S; Ezzedine K; Doussau A; Grandoulier AS; Barcat D; Chatelus E; Diot E; Durant C; Hachulla E; de Korwin-Krokowski JD; Kostrzewa E; Quemeneur T; Paul C; Schaeverbeke T; Seneschal J; Solanilla A; Sparsa A; Bouchet S; Lepreux S; Mahon FX; Chene G; Taïeb A
Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
[TBL] [Abstract][Full Text] [Related]
22. The correlation between durometer score and modified Rodnan skin score in systemic sclerosis.
Moon KW; Song R; Kim JH; Lee EY; Lee EB; Song YW
Rheumatol Int; 2012 Aug; 32(8):2465-70. PubMed ID: 21769489
[TBL] [Abstract][Full Text] [Related]
23. RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.
Distler O; Pope J; Denton C; Allanore Y; Matucci-Cerinic M; de Oliveira Pena J; Khanna D
Respir Med; 2017 Jan; 122 Suppl 1():S14-S17. PubMed ID: 27746061
[TBL] [Abstract][Full Text] [Related]
24. Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study.
Utsunomiya A; Hasegawa M; Oyama N; Asano Y; Endo H; Fujimoto M; Goto D; Ishikawa O; Kawaguchi Y; Kuwana M; Ogawa F; Takahashi H; Tanaka S; Sato S; Takehara K; Ihn H
Mod Rheumatol; 2021 Jan; 31(1):162-170. PubMed ID: 32243215
[TBL] [Abstract][Full Text] [Related]
25. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.
Lafyatis R; Kissin E; York M; Farina G; Viger K; Fritzler MJ; Merkel PA; Simms RW
Arthritis Rheum; 2009 Feb; 60(2):578-83. PubMed ID: 19180481
[TBL] [Abstract][Full Text] [Related]
26. Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis.
Herrick AL; Lunt M; Whidby N; Ennis H; Silman A; McHugh N; Denton CP
J Rheumatol; 2010 Jan; 37(1):116-24. PubMed ID: 19955050
[TBL] [Abstract][Full Text] [Related]
27. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J
Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.
Namas R; Tashkin DP; Furst DE; Wilhalme H; Tseng CH; Roth MD; Kafaja S; Volkmann E; Clements PJ; Khanna D;
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):439-444. PubMed ID: 28544580
[TBL] [Abstract][Full Text] [Related]
29. A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.
Allanore Y; Wung P; Soubrane C; Esperet C; Marrache F; Bejuit R; Lahmar A; Khanna D; Denton CP;
Ann Rheum Dis; 2020 Dec; 79(12):1600-1607. PubMed ID: 32963047
[TBL] [Abstract][Full Text] [Related]
30. A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis.
Genovese MC; Chakravarty EF; Boyle DL; Tutuncu Z; Thorburn CM; Halilhodzic M; Kroll S; Baughman J; Stewart S; Kavanaugh A
J Rheumatol; 2005 Dec; 32(12):2345-50. PubMed ID: 16331761
[TBL] [Abstract][Full Text] [Related]
31. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
32. Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS).
Zheng B; Hudson M; Wang M; Baron M;
Arthritis Res Ther; 2020 Jun; 22(1):132. PubMed ID: 32503616
[TBL] [Abstract][Full Text] [Related]
33. Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.
Khanna D; Furst DE; Hays RD; Park GS; Wong WK; Seibold JR; Mayes MD; White B; Wigley FF; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally EV; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
Ann Rheum Dis; 2006 Oct; 65(10):1325-9. PubMed ID: 16540546
[TBL] [Abstract][Full Text] [Related]
34. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.
Khanna D; Berrocal VJ; Giannini EH; Seibold JR; Merkel PA; Mayes MD; Baron M; Clements PJ; Steen V; Assassi S; Schiopu E; Phillips K; Simms RW; Allanore Y; Denton CP; Distler O; Johnson SR; Matucci-Cerinic M; Pope JE; Proudman SM; Siegel J; Wong WK; Wells AU; Furst DE
Arthritis Rheumatol; 2016 Feb; 68(2):299-311. PubMed ID: 26808827
[TBL] [Abstract][Full Text] [Related]
35. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.
Denton CP; Engelhart M; Tvede N; Wilson H; Khan K; Shiwen X; Carreira PE; Diaz Gonzalez F; Black CM; van den Hoogen FH
Ann Rheum Dis; 2009 Sep; 68(9):1433-9. PubMed ID: 18782794
[TBL] [Abstract][Full Text] [Related]
36. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.
Mendoza FA; Nagle SJ; Lee JB; Jimenez SA
J Rheumatol; 2012 Jun; 39(6):1241-7. PubMed ID: 22467932
[TBL] [Abstract][Full Text] [Related]
37. Changes in disability and their relationship with skin thickening, in diffuse and limited cutaneous systemic sclerosis: a retrospective cohort study.
Peytrignet S; Manning J; Wragg E; Moore T; Samaranayaka M; Dinsdale G; Herrick AL
Scand J Rheumatol; 2019 May; 48(3):230-234. PubMed ID: 30394164
[TBL] [Abstract][Full Text] [Related]
38. Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials.
Kaldas M; Khanna PP; Furst DE; Clements PJ; Kee Wong W; Seibold JR; Postlethwaite AE; Khanna D;
Rheumatology (Oxford); 2009 Sep; 48(9):1143-6. PubMed ID: 19605370
[TBL] [Abstract][Full Text] [Related]
39. Clinical Efficacy and Safety of Bathing with Chinese Medicine Taohong Siwu Decoction () for Treatment of Diffuse Cutaneous Systemic Sclerosis: A Randomized Placebo-Controlled Trial.
Zhou J; Yang D; Zhou SH; Wang JP; Liu YS; Wang SL
Chin J Integr Med; 2018 Mar; 24(3):185-192. PubMed ID: 28197938
[TBL] [Abstract][Full Text] [Related]
40. A data-driven approach finds RNA polymerase III antibody and tendon friction rubs as enrichment tools for early diffuse scleroderma trials.
Domsic RT; Medsger TA; Gao S; Laffoon M; Huang S; Wisniewski S; Spino C; Steen V; Lafyatis R; Khanna D
Rheumatology (Oxford); 2023 Apr; 62(4):1543-1551. PubMed ID: 36031807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
